Chronic Lymphocytic Leukemia
October 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Combination therapy with the type II anti-CD20 antibody obinutuzumab.
Authors:Klein C, Bacac M, Umana P, Fingerle-Rowson G
Institution:a Roche Pharmaceutical Research & Early Development , Roche Innovation Center Zurich , Zurich , Switzerland. Zurich , Zurich , Switzerland. Zurich , Zurich , Switzerland. Switzerland.
Journal:Expert Opin Investig Drugs. 2017 Oct;26(10):1145-1162. doi: 10.1080/13543784.2017.1373087.

2:Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Authors:Hallek M
Institution:Department I of Internal Medicine, Center for Integrated Oncology Koln Bonn, Center of Excellence on "Cellular Stress Responses in Aging-Associated Diseases," University of Cologne, Kerpener Strasse 62, Koln, 50937, Germany.
Journal:Am J Hematol. 2017 Sep;92(9):946-965. doi: 10.1002/ajh.24826.

3:New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.
Authors:Tripathi R, Lee-Verges E, Higashi M, Gimenez N, Rosich L, Lopez-Guerra M, Colomer D
Institution:a Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hematopathology Unit , Hospital Clinic, CIBERONC , Barcelona , Spain.
Journal:Expert Opin Drug Discov. 2017 Oct;12(10):1041-1052. doi: 10.1080/17460441.2017.1362387. Epub 2017 Aug 4.

4:Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Authors:Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG
Institution:Cameron J. Turtle, Kevin A. Hay, Laila-Aicha Hanafi, Shelly Heimfeld, Stanley R. Riddell, and David G. Maloney, Fred Hutchinson Cancer Research Center; Cameron J. Turtle, Sindhu Cherian, Xueyan Chen, Brent Wood, Stanley R. Riddell, and David G. Maloney, University of Washington; Daniel Li, Juno Therapeutics, Seattle, WA; and Arletta Lozanski and John C. Byrd, The Ohio State University, Columbus, OH.
Journal:J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.

5:The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Authors:Tran PN, O'Brien S
Institution:a Division of Hematology-Oncology , University of California Irvine , Orange , CA , USA. , USA.
Journal:Expert Opin Drug Saf. 2017 Sep;16(9):1079-1088. doi: 10.1080/14740338.2017.1344213. Epub 2017 Jun 23.

6:Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Authors:Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhauser M, Iacobelli S, Putter H, Schonland SO, Kroger N
Institution:Medical Department I, University Hospital of the Technical University Dresden, Dresden, Germany.; DKMS Clinical Trials Unit, Dresden, Germany.; Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands.; BMT Unit Department of Haematology, Rigshospitalet, Copenhagen, Denmark.; Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Journal:Br J Haematol. 2017 Aug;178(4):521-533. doi: 10.1111/bjh.14791. Epub 2017 Jun 7.

7:Obinutuzumab: what is there to learn from clinical trials?
Authors:Cartron G, Watier H
Institution:Departement d'Hematologie Clinique, Centre Hospitalier Universitaire (CHU), Montpellier, France. (CNRS), Universite de Montpellier, Montpellier, France.
Journal:Blood. 2017 Aug 3;130(5):581-589. doi: 10.1182/blood-2017-03-771832. Epub 2017 Jun 5.

8:Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
Authors:Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, Cerhan JR, Slager SL, Shanafelt TD
Institution:Mayo Clinic College of Medicine, Rochester, MN, USA.
Journal:Br J Haematol. 2017 Aug;178(3):394-402. doi: 10.1111/bjh.14785. Epub 2017 Jun 4.

9:Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
Authors:Sachanas S, Pangalis GA, Moschogiannis M, Yiakoumis X, Koulieris E, Tsirkinidis P, Kalpadakis C, Rontogianni D
Institution:Department of Hematology, Athens Medical Center, Psychikon Branch, Athens, Greece ssachanas@gmail.com. Greece. Greece. Greece. Greece. Greece. Heraklion, Greece. Athens, Athens, Greece.
Journal:Anticancer Res. 2017 Jun;37(6):3277-3280.

10:Imbruvica(R)black triangle down(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma.
Authors:Murthy V, Weaving S, Paneesha S
Institution:Consultant Haematologist, Heart of England NHS Foundation Trust.
Journal:Br J Nurs. 2017 May 25;26(10):S20-S25. doi: 10.12968/bjon.2017.26.10.S20.

11:Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Authors:Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW
Institution:Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, Australia. Medical Research, Parkville, Australia. Parkville, Australia. Parkville, Australia. Medical Research, Parkville, Australia. Melbourne Hospital, Parkville, Australia. Medical Research, Parkville, Australia. Parkville, Australia. Medical Research, Parkville, Australia. Parkville, Australia. Parkville, Australia.
Journal:Blood. 2017 Jun 22;129(25):3362-3370. doi: 10.1182/blood-2017-01-763003. Epub 2017 May 4.

12:An update for Richter syndrome - new directions and developments.
Authors:Eyre TA, Schuh A
Institution:Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Trust, Oxford, UK. Trust, Churchill Hospital, Oxford, UK. Hospitals NHS Trust, Oxford, UK. Trust, Churchill Hospital, Oxford, UK. Foundation Trust, Oxford, UK.
Journal:Br J Haematol. 2017 Aug;178(4):508-520. doi: 10.1111/bjh.14700. Epub 2017 Apr 25.

13:Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Authors:Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM
Institution:Division of Hematology and.
Journal:Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19.

14:Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Authors:Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM
Institution:Division of Hematology, The Ohio State University, Columbus, OH, USA. Center, Philadelphia, PA, USA. Houston, TX, USA. Houston, TX, USA.
Journal:Br J Haematol. 2017 Jul;178(2):286-291. doi: 10.1111/bjh.14660. Epub 2017 Apr 10.

15:Long-term safety experience with bendamustine for injection in a real-world setting.
Authors:Martin P, Barr PM, James L, Pathak A, Kahl B
Institution:a Division of Hematology/Oncology , New York-Presbyterian/Weill Cornell Medicine , New York , NY , USA. Rochester , NY , USA. Frazer , PA , USA. Louis , MO , USA.
Journal:Expert Opin Drug Saf. 2017 Jun;16(6):647-650. doi: 10.1080/14740338.2017.1318125. Epub 2017 Apr 17.

16:Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Authors:Shustik C, Bence-Bruckler I, Delage R, Owen CJ, Toze CL, Coutre S
Institution:McGill University Health Centre, Montreal, Quebec, Canada. chaim.shustik@mcgill.ca. Canada. Calgary, AB, Canada. BC Cancer Agency and The University of British Columbia, Vancouver, BC, Canada. USA.
Journal:Ann Hematol. 2017 Jul;96(7):1185-1196. doi: 10.1007/s00277-017-2982-1. Epub 2017 Apr 7.

17:Duvelisib: a phosphoinositide-3 kinase delta/gamma inhibitor for chronic lymphocytic leukemia.
Authors:Vangapandu HV, Jain N, Gandhi V
Institution:a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA. Houston , TX , USA. Cancer Center , Houston , TX , USA.
Journal:Expert Opin Investig Drugs. 2017 May;26(5):625-632. doi: 10.1080/13543784.2017.1312338. Epub 2017 Apr 13.

18:Lenalidomide in the treatment of chronic lymphocytic leukemia.
Authors:Itchaki G, Brown JR
Institution:a Department of Medical Oncology , Dana Farber Cancer Institute , Boston , MA , USA. USA.
Journal:Expert Opin Investig Drugs. 2017 May;26(5):633-650. doi: 10.1080/13543784.2017.1313230. Epub 2017 Apr 17.

19:Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Authors:Molica S
Institution:a Department of Hematology-Oncology , Azienda Ospedaliera Pugliese-Ciaccio , Catanzaro , Italy.
Journal:Expert Rev Hematol. 2017 May;10(5):425-432. doi: 10.1080/17474086.2017.1313108. Epub 2017 Apr 12.

20:Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Authors:Kaur V, Swami A
Institution:Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA. varinderdhaliwal@gmail.com.
Journal:Ann Hematol. 2017 Jul;96(7):1175-1184. doi: 10.1007/s00277-017-2973-2. Epub 2017 Mar 24.

21:Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Authors:Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foa R, Gentile M
Institution:Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. Mazzoni, Ascoli Piceno. Roma Tor Vergata, Rome. Policlinico, Milan. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome.
Journal:Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

22:Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
Authors:Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM
Institution:Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA. Houston, TX, USA.
Journal:Br J Haematol. 2017 May;177(4):567-577. doi: 10.1111/bjh.14596. Epub 2017 Mar 14.

23:Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Authors:Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Chao Family Comprehensive Cancer Center, University of California-Irvine, Orange, California.
Journal:Cancer. 2017 Jun 15;123(12):2268-2273. doi: 10.1002/cncr.30596. Epub 2017 Feb 7.

24:A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.
Authors:Ogawa Y, Izutsu K, Kiguchi T, Choi I, Takatsuka Y, Ando K, Suzumiya J
Institution:Department of Hematology and Oncology, Tokai University Hospital, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. yoshioga@is.icc.u-tokai.ac.jp. of Public School Teachers, Fukuyama, Japan. Fukuoka, Japan. Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. Japan.
Journal:Int J Hematol. 2017 May;105(5):631-637. doi: 10.1007/s12185-016-2178-9. Epub 2017 Feb 3.

25:Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
Authors:King AC, Peterson TJ, Horvat TZ, Rodriguez M, Tang LA
Institution:1 Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Journal:Ann Pharmacother. 2017 May;51(5):410-416. doi: 10.1177/1060028016685803. Epub 2017 Jan 6.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: June 20, 2017
176 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL42660857

Coupon Expires: November 17, 2017



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.